Aurobindo Pharma Limited has informed the Exchange regarding a press release dated December 28, 2021, titled "Aurobindo announces DCGI s permission to manufacture and market its generic version of Molnupiravir to be marketed as Molnaflu��, licensed from MSD and Ridgeback".